Objective: The primary objective of this systematic review is to present current knowledge about the oncobiome of gynecological cancers. Methods: Our systematic review contains data about the oncobiome of uterine corpus cancer, ovarian cancer and cervical cancer. Articles about other gynecological cancers were excluded. Results: A total of 72 articles were included in our systematic review. In uterine corpus cancer, cervical cancer and ovarian cancer, representatives of bacteria, fungi, viruses and parasites can be found. The oncobiome of ovarian cancer is connected with the oncobiome of head and neck cancers. Our systematic review proved that the human papilloma virus is connected with ovarian and cervical cancer. Gut dysbiosis can be used as a marker of ovarian cancer. In cervical cancer, we found the difference between the microbiota of healthy patients and patients with cervical cancer. Methylobacter, Robignitomaculum, Klebsiella, Micromonospora and Microbispora have an impact on overall survival. The microbiome of uterine corpus cancer is more differentiated than in cancer-free samples. Chronic endometrial inflammation has an impact on endometrial microbiome. Discussion: Treatment of gynecological cancers is changing permanently. Chemotherapy, as a systematic treatment, is being left in the past. Modern methods of therapy are addressed to specific genes. In the past, researchers claimed that tumors are sterile. However, the newest research indicates that malignancies were found to have genetic fragments of pathogens, which can be used as vectors for medications or as markers for the detection of a specific malignancy. Three most common gynecological cancers are as follows: endometrial cancer, ovarian cancer and cervical cancer. Each of these has their specific microbiome, which can be used for oncological treatment. These discoveries create possibilities for new, efficient methods of treatment. This systematic review analyzes publications about the composition of the gynecological tumor microenvironment, correlation between microbiomes of different organs, the female reproductive tract and the microbiome of the female reproductive tract during malignancy. Moreover, we provide information on the influence of some pathogens on the treatment.
Background/Objectives: The treatment of ovarian cancer (OC), which is predominantly diagnosed in advanced stages, poses a significant challenge to modern gynecologic oncology practice. A significant proportion of patients exhibit chemoresistance, underscoring the need for novel therapeutic interventions. This challenge is further compounded by the immunogenic nature of this neoplasm, prompting the exploration of alternative therapies. A notable example is the use of trastuzumab-deruxtecan (T-DXd), an antibody-drug conjugate (ADC), that has demonstrated encouraging outcomes in preliminary studies and has the potential to become a new treatment option. This systematic review aims to prove that. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) structure was employed to systematically search the PubMed and Scopus databases from December 2024. Furthermore, authors employed materials from the FDA’s official website and registry of clinical trials that are currently recruiting participants for T-DXd’s studies. Eligible studies included randomized controlled trials and observational studies assessing T-DXd in patients with OC. Outcomes of interest were objective response rate (ORR), median overall survival, adverse effects, and progression-free survival. Data was synthesized narratively. Results: Following a thorough review of available literature, 30 scientific papers were selected for inclusion. A total of 598 patients participated in clinical trials. The most common adverse effects were blurred vision and nausea, generally manageable. The risk of bias was low in most studies. Conclusions: T-DXd shows promising efficacy. A comparison of T-DXd with the ADC currently approved for OC therapy reveals that both demonstrate similar median overall survival and ORRs. However, the drug has exhibited significant adverse effects in breast cancer trials and has been studied on a relatively small number of patients. Therefore, further clinical trials focusing on OC patients are necessary to better assess the safety and efficacy of T-DXd in this population.
Background: Uterine fibroids are the most common tumors in gynecology, detected in up to 80% of patients at various points in their lives. Uterine sarcomas account for 3% to 7% of all uterine cancers. The diagnosis of uterine fibroids is possible through ultrasonography (US), but this method has many limitations. More accurate examinations include magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. Methods: This study evaluates MRI and PET in differentiating uterine fibroids from sarcomas. MRI uses T2-weighted and diffusion-weighted imaging (DWI), while PET assesses metabolism and estrogen receptor activity using [18F] fluorodeoxyglucose (FDG) and 16α-[18F]-fluoro-17β-estradiol (FES). Results: MRI allows for the identification of uterine fibroids when they exhibit good delineation and low intensity in T2-weighted images and DWI. Uterine sarcoma is characterized by moderate to high signal intensity on T2-weighted imaging, irregular borders, high signal intensity at high DWI values, and a decreased apparent diffusion coefficient. PET imaging with FDG and FES is a useful tool in differentiating uterine fibroids from sarcomas. Uterine sarcomas exhibit greater FDG uptake than smooth muscle fibroids, although cases of similar uptake do occur. On the other hand, FES provides information about estrogen receptors (ERs). Conclusions: Future research should focus on conducting standardized imaging studies, which would facilitate the inclusion of larger patient cohorts. This, in turn, would enable the development of specific diagnostic guidelines, ultimately leading to more accurate diagnoses and reducing the difficulty of differentiating these tumors through imaging.
Ovarian cancer is a major cause of gynecological cancer mortality, frequently associated with platinum-resistant recurrences. Given the limited efficacy of conventional chemotherapy in this setting, alternative targeted therapeutics are needed. Mirvetuximab soravtansine (MIRV) is an antibody–drug conjugate designed to deliver the cytotoxic maytansinoid DM4 to folate receptor alpha (FRα)-overexpressing cells. This systematic review of PubMed, ClinicalKey, and SpringerLink databases (2019–2026) evaluates five publications across three clinical trials (one phase II, two phase III) encompassing 925 patients with platinum-resistant disease. Notably, the phase III MIRASOL trial demonstrated improved survival outcomes with MIRV over standard chemotherapy, extending median overall survival (16.46 vs. 12.75 months; HR 0.67) and progression-free survival (5.62 vs. 3.98 months; HR 0.65), with an objective response rate (ORR) of 42.3% versus 15.9%. Furthermore, the single-arm phase II SORAYA trial reported an ORR of 32.4% in pretreated patients, including those with prior PARP inhibitor and bevacizumab exposure. Although the preceding FORWARD I trial missed its primary endpoint in the unselected population, its high-FRα subgroup analysis revealed a clinical benefit that influenced subsequent biomarker-driven enrollment strategies. From a safety perspective, MIRV exhibited lower rates of severe neutropenia and anemia than chemotherapy, with toxicities primarily consisting of manageable, reversible ocular events. Ultimately, MIRV serves as a therapeutic option for platinum-resistant, FRα-positive ovarian cancer, offering survival advantages; however, rigorous biomarker-based screening remains necessary to optimize therapeutic outcomes.
4 February 2026 in Journal of Pre-Clinical and Clinical Research
Introduction and Objective. For a long time, radical surgery was the standard treatment for cervical cancer. In earlystage disease, hysterectomy with lymphadenectomy was commonly performed, which forever precluded any procreative plans. The increasing number of newly-diagnosed cervical cancer cases among women of reproductive age has led to the development of fertility-preserving treatments and minimally invasive techniques. Review Methods. The review outlines fertility-sparing treatment options for patients of childbearing age diagnosed with cervical cancer. PubMed and Google Scholar (2016-2024) were searched using the terms: cervical cancer, fertility sparing treatment, fertility preservation, trachelectomy, radical trachelectomy, neoadjuvant chemotherapy, cervical cancer treatment, conization and simple trachelectomy from 5 March-28 March 2025. Original papers, literature review, case reports, randomized clinical trials and meta-analysis were included. Manuscripts not written in English were excluded excluded. Brief description of the state of knowledge. Depending on the stage of the cancer, options such as conization, trachelectomy, or neoadjuvant chemotherapy can help preserve fertility while avoiding radical procedures. The methods are evaluated for oncological outcomes, including metastasis and recurrence, and for reproductive outcomes, such as pregnancy. Summary. The review presents current fertility-sparing surgical methods as well as chemotherapeutic approaches used to preserve fertility in women undergoing treatment for cervical cancer, the outcomes and eligibility criteria. The growing clinical relevance of fertility preservation underscores its increasing role in individualized treatment planning for cervical cancer patients.
The classification of endometrial cancer based on histological examination often fails to accurately predict treatment outcomes for patients. The Cancer Genome Atlas (TCGA) has proposed a new molecular model that more accurately identifies the tumour subtype, enabling more precise treatment. However, its implementation in daily practice remains a challenge. This systematic review assesses the key role of targeted next-generation sequencing (NGS) in refining the TCGA model and resolving these diagnostic ambiguities. A systematic review was conducted using the PubMed, Scopus, and Embase databases, focusing on studies published mainly between 2019 and 2025. Original studies and clinical guidelines concerning the evaluation of targeted NGS panels, surrogate markers, and the clinical significance of molecular subtypes in endometrial cancer were analysed. Based on the PRISMA guidelines, 11 relevant studies were used in the review. NGS is of key importance, particularly for the detection of POLE gene mutations that cannot be identified using traditional immunohistochemistry. The studies confirm that NGS accurately classifies tumours that exhibit more than one molecular feature. Although sequencing requires more time and resources, it provides a more objective and reproducible diagnostic model. Furthermore, NGS panels currently allow patients to be divided into four prognostic groups with a 100% survival rate in the POLE subtype. Across independently reported cohorts, concordance between NGS and IHC for MMR/p53 status ranged from roughly 65% to 98% depending on the platform and gene target, and NGS-based germline testing identified Lynch syndrome in 9–10% of patients screened; targeted panels also detected homologous-recombination-repair alterations (e.g., BRCA1/2, ATM, CHEK2) relevant to PARP-inhibitor eligibility. NGS combined with immunohistochemistry enables the most accurate diagnosis of patients with endometrial cancer. This combined approach reduces diagnostic errors and also provides the basis for decisions regarding personalised treatment. The introduction of targeted sequencing as a standard clinical tool allows for greater precision in tumour classification and improves the quality of patient care.